Is Insulin a Peptide Hormone? Structure and C-Peptide

The short answer

Yes, insulin is a peptide hormone. It is a small protein made of amino acids joined by peptide bonds, which places it in the peptide (or polypeptide) hormone family rather than among steroid or amine hormones. Because insulin is a peptide, it is built on ribosomes from a gene transcript, folded and processed inside the cell, stored in granules, and released into the bloodstream, where it acts on receptors at the surface of target cells. A review of insulin biosynthesis described this whole route from gene to secreted hormone as a multi-step process inside the pancreatic beta cell (PMID 32894308).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about blood sugar, diabetes, laboratory testing or prescription medicines.

What "peptide hormone" means in plain language

Hormones are signalling molecules released by one tissue that act on another. They fall into broad chemical classes. Peptide hormones are chains of amino acids. Steroid hormones are built from cholesterol. Amine hormones are derived from single amino acids. Insulin sits firmly in the first group, and the literature on beta cell biology treats it throughout as a protein product whose synthesis, folding and packaging follow the rules of the secretory protein pathway (PMID 32894308). Because peptide hormones are water soluble and cannot cross cell membranes freely, they signal from the outside of the cell through surface receptors.

The terms "peptide hormone" and "polypeptide hormone" are used almost interchangeably for insulin. "Polypeptide" simply emphasises that the chain is long enough to fold into a defined three-dimensional shape. For broader background on this hormone class, see the overview at peptide hormones.

Insulin structure: two chains, 51 amino acids, three disulfide bonds

Mature human insulin consists of two separate amino acid chains, named A and B, totalling 51 amino acids: the A chain contributes 21 residues and the B chain 30. The chains are held together by two disulfide bonds between cysteine residues, and a third disulfide bond forms within the A chain itself. An evolutionary analysis of insulin folding examined how this disulfide-linked architecture sits close to the limit of what a small protein can reliably fold into, and the researchers connected that constrained foldability to the consequences of mutations in the insulin gene (PMID 33154160).

Those disulfide bonds matter because they lock the A and B chains together after the connecting segment has been removed. Work on insulin foldability reported that the sequence tolerates relatively little disruption before folding and processing fail (PMID 33154160), and a review of proinsulin proteostasis described how misfolded precursor accumulating in the endoplasmic reticulum is a recognised feature of beta cell stress (PMID 40177516).

From preproinsulin to proinsulin to insulin plus C-peptide

Insulin is not translated in its final form. The pathway described in the biosynthesis literature runs in stages (PMID 32894308):

1. Preproinsulin. The initial translation product carries a signal peptide that directs the growing chain into the endoplasmic reticulum. A 2024 study in Diabetes investigated the Sec61 translocon in this entry step and reported a role for Sec61\u03b12 in insulin biosynthesis in beta cells (PMID 39325584).
2. Proinsulin. After the signal peptide is removed, the remaining single chain folds and forms its disulfide bonds. A review of proinsulin proteostasis summarised how folding quality control at this stage influences beta cell health (PMID 40177516).
3. Cleavage. Proinsulin moves through the Golgi into immature secretory granules, where prohormone convertases and carboxypeptidase cut out the connecting segment. A review of insulin trafficking and exocytosis described granule maturation as the compartment in which this conversion and subsequent storage occur (PMID 31039435).
4. Storage. Mature insulin is stored with zinc inside dense-core granules; a review of granule contents described the internal chemistry and composition of these vesicles (PMID 34436456).

The cut that converts proinsulin into insulin releases two products at once: the two-chain hormone and the connecting peptide. That is why C-peptide and insulin leave the beta cell in roughly equal molar amounts, a relationship set out in a biochemistry review of C-peptide (PMID 30252282).

What C-peptide is and why laboratories measure it

C-peptide is the connecting fragment excised from proinsulin during processing. A biochemistry review described it as a product of proinsulin cleavage that is co-secreted with insulin and that is used as an index of endogenous insulin production, because it is not present in manufactured insulin preparations (PMID 30252282). That distinction is the basis of its laboratory role.

Whether C-peptide does anything of its own has been investigated. A review of C-peptide signalling summarised evidence that the peptide binds to cell membranes and can trigger intracellular signalling events rather than acting purely as an inert by-product (PMID 15198369). This remains a research question rather than a settled piece of clinical practice, and nothing on this page should be read as guidance about testing or treatment.

Processing efficiency itself has been studied as a signal of beta cell stress. A review of biomarkers in type 1 diabetes discussed circulating proinsulin and the proinsulin to C-peptide ratio among measures proposed to reflect beta cell stress and death (PMID 27541297). In other words, when conversion of precursor to mature hormone is incomplete, the mix of molecules reaching the blood changes.

How insulin is released and how it acts

Release is tied to nutrient availability. A review of insulin synthesis and secretion described glucose as the principal stimulus for secretion from beta cells and examined how beta cell dysfunction develops in diabetes (PMID 22974359). The mechanics of the final step were covered in a review of insulin trafficking and exocytosis, which described how granules are transported and fuse with the plasma membrane to discharge their contents (PMID 31039435).

Beta cells are also not uniform. A review of human beta cell heterogeneity reported that individual cells within islets differ in gene expression and secretory behaviour, so the islet behaves as a population rather than a single cell type copied many times (PMID 31500834).

Receptor action

Because insulin is a peptide and cannot pass through the lipid membrane, it acts from outside the cell. It binds the insulin receptor, a transmembrane protein with tyrosine kinase activity on its inner face. Binding changes the receptor's shape, the kinase domains phosphorylate each other and then intracellular substrate proteins, and a signalling cascade follows that increases glucose uptake into muscle and fat tissue and shifts cells toward storage of fuel. This is the classic peptide hormone arrangement: the message is delivered at the surface and relayed inward by second messengers and phosphorylation events. The physiological outcome, lowering of circulating glucose, is the counterweight to glucagon action, compared in the companion guide on glucagon versus insulin, and a review of secretion and beta cell dysfunction framed the loss of adequate insulin output as central to diabetes (PMID 22974359).

Why the peptide nature of insulin shapes how it is manufactured

Peptide hormones are digested in the gut like other proteins, which is one reason insulin medicines are not swallowed as ordinary tablets. Being a peptide also determines how insulin is produced industrially. A review of downstream processing described the manufacture of recombinant human insulin and its analogues from inclusion bodies expressed in Escherichia coli, covering the recovery, refolding and purification steps needed to obtain correctly folded product (PMID 34336550). Correct disulfide pairing during refolding is the central technical challenge, which connects directly to the foldability constraints analysed in the evolutionary study of insulin (PMID 33154160).

Regulatory fact: insulin products intended for human use are prescription medicines, dispensed and supervised by licensed prescribers. This page does not discuss how any insulin product is used, and every question about whether, when or how an insulin medicine applies to an individual belongs with a prescribing clinician.

Proinsulin processing problems: What Studies Report

Published work has examined what happens when the steps above do not run cleanly. A review of proinsulin proteostasis reported that failure of precursor folding and quality control in the endoplasmic reticulum is associated with beta cell stress and has been linked to diabetes pathology (PMID 40177516). A review of biomarkers in type 1 diabetes reported that elevated proinsulin relative to C-peptide has been proposed as an indicator of stressed beta cells (PMID 27541297). An analysis of insulin foldability reported that mutations pushing the molecule beyond its narrow folding tolerance carry medical implications, including monogenic forms of diabetes (PMID 33154160). These are descriptions of disease biology drawn from the literature, not statements about any individual's health.

Limits of what this page covers

The sources summarised here are mostly reviews and mechanistic studies of beta cell biology, so they describe pathways and measurements rather than outcomes of any intervention. Review articles compress large bodies of primary work and can simplify disagreement between laboratories. Findings generated in cell models or animal tissue do not automatically transfer to human physiology, and a review of human beta cell heterogeneity made clear that even within one pancreas the cells differ (PMID 31500834). Nothing here describes doses, products or personal use.

Related reading

• Peptide hormones: how this class of signalling molecule works
• Glucagon versus insulin: two peptide hormones compared

References

• Biochemistry, C Peptide (StatPearls, 2023)
• Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes (Current Diabetes Reviews, 2013)
• Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies (Bioresources and Bioprocessing, 2021)
• Biomarkers of \u03b2-Cell Stress and Death in Type 1 Diabetes (Current Diabetes Reports, 2016)
• The making of insulin in health and disease (Diabetologia, 2020)
• The C-peptide signaling (Experimental Diabesity Research, 2004)
• A review on insulin trafficking and exocytosis (Gene, 2019)
• Corrigendum: Exploring proinsulin proteostasis: insights into beta cell health and diabetes (Frontiers in Molecular Biosciences, 2025)
• Heterogeneity of human pancreatic \u03b2-cells (Molecular Metabolism, 2019)
• Inside the Insulin Secretory Granule (Metabolites, 2021)
• Evolution of insulin at the edge of foldability and its medical implications (PNAS, 2020)
• Role of Sec61\u03b12 Translocon in Insulin Biosynthesis (Diabetes, 2024)